HAEMATOLOGICAL AND BIOCHEMICAL BLOOD PARAMETERS IN EPILEPTIC DOGS DURING THERAPY
DOI:
https://doi.org/10.37000/abbsl.2026.120.27Keywords:
dogs, epilepsy, serum biochemistry, haemoglobin, erythrocytes, anticonvulsant therapyAbstract
Immunomodulatory treatment is increasingly considered for some forms of drug-resistant epilepsy, which points to a possible immune component in the disease. The aim of our study was to assess how the immunomodulatory drug Encad (Енкад), added to a combined treatment protocol, affects haematological and biochemical blood parameters in dogs with epilepsy. The study was carried out at the Eksvet veterinary clinic in Odesa on 21 dogs aged 2 to 6 years with diagnosed epilepsy. The dogs were divided into two groups according to the treatment protocol.
The red blood cell and platelet counts and indices differed between the groups depending on the treatment. In the control group (phenobarbital + potassium bromide), there was a clear trend towards suppression of erythropoiesis and the development of anaemia over 21 days. In the experimental group, where Encad (Енкад) was added to the protocol, the negative effect of the basic anticonvulsants on the blood was not observed, and red blood cell parameters even improved. The red blood cell count increased from 6.93 ± 0.36 to 7.88 ± 0.23 × 10¹²/L (p < 0.05), and haemoglobin rose by 5.9 g/L, whereas in the control group it tended to decrease. Serum sodium, potassium and chloride levels remained stable in both groups, with no significant differences between them. Blood glucose was also stable in both groups and stayed within the normal range (5.75–5.93 mmol/L), so the protocols did not appear to affect carbohydrate metabolism.
Adding Encad (Енкад) had a significant liver-protective effect: ALT and AST activity was significantly lower than in the control group (p < 0.05), and fluid, electrolyte and glucose balance remained normal. Encad also stimulated blood formation: the red blood cell count rose to 7.88 ± 0.23 × 10¹²/L and haemoglobin to 174.70 ± 8.39 g/L (p < 0.05). So, adding Encad (Енкад) to the standard epilepsy treatment in dogs for 21 days increased red blood cell count and haemoglobin and reduced ALT and AST activity, while the control group showed a downward trend in red blood cell parameters and an increase in ALT. Because the observation period was short and the groups were small, these results are preliminary and need to be confirmed in a larger study with a wider range of biochemical tests.
References
Kompendium. (n.d.). Enkad-Biolik: Instruktsiia iz zastosuvannia [Encad-Biolik: Instructions for use]. Retrieved November 10, 2026, from https://compendium.com.ua/dec/270060
Zakon Ukrainy «Pro zakhyst tvaryn vid zhorstokoho povodzhennia» № 3447-IV (2006). https://zakon.rada.gov.ua/laws/show/3447-15#Text
Reznikov, O. H. (2003). Zahalni etychni pryntsypy eksperymentiv na tvarynakh. Pershyi natsionalnyi konhres z bioetyky. Endokrynolohiia,T. 8, № 1., S. 142–145
Andrić, N., Popović, N., Stepanović, P., Francuski, J., & Đurđević, D. (2010). Biochemical changes in the blood serum of dogs treated with phenobarbital. Acta Veterinaria (Beograd), 60(5–6), 573–584. https://doi.org/10.2298/AVB1006573A
Council of Europe (1986). European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes. European Treaty Series, No. 123. https://rm.coe.int/168007a67b
Dalmau, J., Geis, C., & Graus, F. (2017). Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous System. Physiological reviews, 97(2), 839–887. https://doi.org/10.1152/physrev.00010.2016
Müller, P. B., Taboada, J., Hosgood, G., Partington, B. P., VanSteenhouse, J. L., Taylor, H. W., & Wolfsheimer, K. J. (2000). Effects of long-term phenobarbital treatment on the liver in dogs. Journal of veterinary internal medicine, 14(2), 165–171. https://doi.org/10.1892/0891-6640(2000)014<0165:eolpto>2.3.co;2
Gaskill, C. L., Hoffmann, W. E., & Cribb, A. E. (2004). Serum alkaline phosphatase isoenzyme profiles in phenobarbital-treated epileptic dogs. Veterinary clinical pathology, 33(4), 215–222. https://doi.org/10.1111/j.1939-165x.2004.tb00376.x
Berendt, M., Farquhar, R. G., Mandigers, P. J., Pakozdy, A., Bhatti, S. F., De Risio, L., Fischer, A., Long, S., Matiasek, K., Muñana, K., Patterson, E. E., Penderis, J., Platt, S., Podell, M., Potschka, H., Pumarola, M. B., Rusbridge, C., Stein, V. M., Tipold, A., & Volk, H. A. (2015). International veterinary epilepsy task force consensus report on epilepsy definition, classification and terminology in companion animals. BMC veterinary research, 11, 182. https://doi.org/10.1186/s12917-015-0461-2
Lancaster, E. (2016). The diagnosis and treatment of autoimmune encephalitis. Journal of Clinical Neurology, 12(1), 1–13. https://doi.org/10.3988/jcn.2016.12.1.1
Gaskill, C. L., Miller, L. M., Mattoon, J. S., Hoffmann, W. E., Burton, S. A., Gelens, H. C., Ihle, S. L., Miller, J. B., Shaw, D. H., & Cribb, A. E. (2005). Liver histopathology and liver and serum alanine aminotransferase and alkaline phosphatase activities in epileptic dogs receiving phenobarbital. Veterinary pathology, 42(2), 147–160. https://doi.org/10.1354/vp.42-2-147
Melvin, J. J., & Huntley Hardison, H. (2014). Immunomodulatory treatments in epilepsy. Seminars in pediatric neurology, 21(3), 232–237. https://doi.org/10.1016/j.spen.2014.08.001
Bersan, E., Volk, H. A., Ros, C., & De Risio, L. (2014). Phenobarbitone-induced haematological abnormalities in idiopathic epileptic dogs: prevalence, risk factors, clinical presentation and outcome. The Veterinary record, 175(10), 247. https://doi.org/10.1136/vr.102158
Junyent, F., Utrera, J., Romero, R., Pallàs, M., Camins, A., Duque, D., & Auladell, C. (2009). Prevention of epilepsy by taurine treatments in mice experimental model. Journal of neuroscience research, 87(6), 1500–1508. https://doi.org/10.1002/jnr.21950
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.